- Home » News and EventsPage 2
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Jan 5, 2023
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina
Dec 14, 2022
The new facility within North Carolina’s Research Triangle, will offer comprehensive analytical development and testing for biologic drug modalities.
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Gosselies, Belgium
Dec 8, 2022
The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Nov 3, 2022
The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.
Catalent Expands Biologics Analytical Capabilities with New Laboratories at Center of Excellence in Kansas City, Missouri
Oct 20, 2022
Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
Jul 7, 2022
Xenetic Biosciences today announced it has entered into a manufacturing agreement with Catalent, which will include cGMP manufacturing for the recombinant protein, Human DNase I.
Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
May 16, 2022
The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.
Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech
Apr 25, 2022
Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.
Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility
Apr 21, 2022
The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.